Nextage Therapeutics Ltd (TASE: NXTG) CEO Abraham Dreazen speaks to Proactive New York about the Israel-based drug development company's efforts to eliminate the toxicity and safety issues associated with the psychedelic molecule ibogaine.
Nextage, through its subsidiary IMIO Life, has licensed its Brain Targeting Liposome System (BTLS) delivery technology to US-based MindMed (NASDAQ:MNMD, NEO:MMED), who have been collaborating together to optimize the delivery of ibogaine, and will share development costs and intellectual property arising from the collaboration.